

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q3 13-14	Q3 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
Domestic	7,651	7,370	3.8%	23744	22457	5.7%
Formulations	5,883	5,692	3.4%	18,398	17,524	5.0%
API	112	160	-30.0%	431	384	12.2%
Wellness	1,034	1,018	1.6%	3,223	3,016	6.9%
Animal Health & Others	622	500	24.3%	1,692	1,533	10.4%
Exports	10,061	7,265	38.5%	25,431	20,481	24.2%
Formulations	9,167	6,525	40.5%	22,877	18,285	25.1%
US	6,316	3,920	61.1%	14,921	11,186	33.4%
Europe	1,186	1,119	6.0%	3,056	2,736	11.7%
Japan	145	180	-19.5%	397	462	-14.1%
Brazil	639	666	-4.1%	1,780	1,797	-0.9%
Mexico	49	0		84	0	
Emerging Mkts & Others	832	640	30.1%	2,638	2,104	25.4%
API	731	618	18.3%	2,127	1,856	14.6%
Animal Health & Others	163	122	33.6%	427	340	25.5%
JVs & Alliances	1,012	1,307	-22.6%	3,388	3,918	-13.5%
Total	18,724	15,942	17.5%	52,562	46,855	12.2%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q3 13-14	Q3 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
Other Operating Income	337	431	-21.9%	1,118	1,566	-28.6%
Dossier Fees	0	0		0	2	-100.0%
Royalty Income	51	0		226	296	-23.6%
Net Gain on foreign currency transactions and translation (Refer Note below)	111	117	-5.5%	286	593	-51.8%
Others	175	314	-44.2%	606	675	-10.1%

Note : Apart from this gain, there was a net loss of Rs. 559 Mio. in Q3 13-14 on hedging and on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods and Sales. Thus, on aggregate level, there was a loss of Rs. 448 Mio. on operating transactions (above EBIDTA line) in Q3 13-14 vs gain of Rs. 199 Mio. in Q3 12-13. See details below for more clarity.

Rs. Mio.	Q3 13-14	Q3 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
Other Income	128	123	3.9%	375	283	32.8%
Interest & Dividend income	93	77	20.3%	273	218	25.2%
Profit on sale of investments	21	9	145.0%	58	14	305.3%
Profit on sale of assets	0	0		0	0	
Others	14	37	-63.4%	45	51	-11.2%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q3 13-14	Q3 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
A. On operating transactions (above EBIDTA line)	448	-199	325.3%	203	-15	1465.4%
a. Included in other income	-111	-117	5.5%	-286	-593	51.8%
b. Included in sales	223	0		550	0	
c. Included in cost of goods	336	-82	509.8%	-61	578	-110.6%
B. On Foreign Currency Borrowings (part of interest cost)	-103	33	-412.1%	-247	437	-156.5%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	345	-166	308.0%	-44	422	-110.4%

Details of R&D Expenses

Rs. Mio.	Q3 13-14	Q3 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
Total R&D Expenses	1,234	1,407	-12.3%	3,575	3,451	3.6%

Consolidated Capex for Apr-Dec 13

Rs. 4904
Mio.

R&D capex included in above for Apr-Dec 13 :

Rs. 61
Mio.